InhA-IN-13

InhA-IN-13 (compound 17) inhibits Mycobacterium tuberculosis mc² 6230 with an MIC of 0.25 μg/mL^[1].
InhA-IN-13 (MIC > 32 μg/mL) loses efficacy against isoniazid (HY-B0329)-resistant Mycobacterium tuberculosis mc² 8243, with MIC > 32 μg/mL^[1].
InhA-IN-13 (1×-8× MIC; 5-10 days) exerts a bactericidal effect against Mycobacterium tuberculosis mc² 6230, producing approximately a 3-log₁₀ CFU reduction at 8× MIC on day 5 and at 4×-8× MIC on day 10^[1].
InhA-IN-13 (1×-8× MIC; 12 days) exhibits time- and concentration-dependent bactericidal activity against Mycobacterium tuberculosis mc² 6230, achieving approximately a 3-log₁₀ reduction at 8× MIC on day 9^[1].
InhA-IN-13 (parental MIC 0.25 μg/mL; mutant 17^r-1 MIC > 32 μg/mL) selects for resistant Mycobacterium tuberculosis mc² 6230 mutants with MIC > 32 μg/mL and a MIC shift of at least 128-fold^[1].
InhA-IN-13 (17-8× MIC > 16 μg/mL; > 64-fold shift) selects Mycobacterium tuberculosis mc² 6230 mutants with MIC shifts > 64-fold that carry multiple InhA substitutions, supporting the involvement of InhA in its antimycobacterial activity^[1].

InhA-IN-13 (1×-8× MIC) reduces the burden of Mycobacterium tuberculosis H37Ra in THP-1 macrophages in a concentration-dependent manner, achieving significant clearance at 8× MIC (MIC 0.25 μg/mL)^[1].

InhA-IN-13 exhibits low acute cytotoxicity in HepG2 cells (CC₅₀ > 100 μg/mL), with a selectivity index > 400^[1].